Tigecycline Treatment of Urinary Tract Infection and Prostatitis: Case Report and Literature Review

Abstract

1suggested that the clinical and microbiological outcomes of tigecycline monotherapy were similar to those of empiric antibiotic regimens in the treatment of complicated skin and skin structure infections, intra-abdominal infections, and community-acquired pneumonia and other infections caused by methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). However, the incidence of adverse events, particularly nausea, was significantly higher with tigecycline than with the comparators. 1 In September 2010, the US Food and Drug Administration issued a safety communication suggesting an increased risk of death with tigecycline relative to other antibiotics used to treat similar infections. 2 The risk was greatest for patients with hospital-acquired pneumonia, especially ventilator-associated pneumonia. The clinical use of tigecycline therapy is generally reserved for treatment of multidrug-resistant (MDR) organ isms. There are very limited data regarding its use in the treat ment of urinary tract infections, as urinary excretion is a minor route of elimination for this drug. Even with no clinical trials, the drug has been suggested as an alternative for the treatment of complicated and nosocomial or catheter-related urinary tract infections caused by MDR Enterobacteriaceae, Acinetobacter baumannii, and VRE. 3